CBPP Spotlight Live January 2021: Hematologic Malignancies | Case-Based Peer Perspectives Spotlight Live

KEY OPINION LEADERS REVIEW CASE SCENARIOS IN TARGETED ONCOLOGYTM LIVE DISCUSSIONS

Necessity of Transplant Considered in Multiple Myeloma

February 09, 2021

Clinical Articles

Sagar Lonial, MD, a professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, and the chief medical officer of Winship Cancer Institute of Emory University, explains the need for transplant in patients with multiple myeloma.

Emerging Prognostic Tools for Myelofibrosis Further Refine Disease Status

February 02, 2021

Clinical Articles

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, reviewed the prognostic tools used to find indicators of response to treatment in patients with myelofibrosis, during a Targeted Oncology Case-Based Peer Perspective Roundtable discussion.

Data From the RESPONSE Studies Drive Ruxolitinib Use in Polycythemia Vera

January 27, 2021

Clinical Articles

The way I practice, personally, is that if they are older than 60 years, they are automatically high risk, and I will start hydroxyurea. In PV, being over 60 years and/or prior thrombosis automatically makes the patient high risk, so you should probably be starting a cytoreductive therapy.